M8819
Mannide monooleate
from plant
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
CAS Number:
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
MDL number:
InChI
1S/C24H44O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(27)29-19-21(26)24-23(28)20(25)18-30-24/h9-10,20-21,23-26,28H,2-8,11-19H2,1H3/b10-9-/t20-,21+,23+,24+/m0/s1
SMILES string
CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O
InChI key
NWGKJDSIEKMTRX-AAZCQSIUSA-N
biological source
plant
form
liquid
color
dark brown
storage temp.
room temp
Quality Level
Looking for similar products? Visit Product Comparison Guide
General description
Mannide monooleate is a lipohilic surfactant. It is also a non-ionic surface active emulsifier.
Application
Mannide monooleate has been used in a study to assess Freund′s incomplete adjuvant emulsion system, which is used in vaccine therapy. It has also been used in a study to investigate the metabolic fate of mineral oil adjuvants using 14C-labeled tracers.
Biochem/physiol Actions
Mannide monooleate is an emulsifying agent utilized in Freund′s incomplete adjuvant, although reactogenicity is an issue with human use.
Other Notes
To gain a comprehensive understanding of our extensive range of Polysaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R O Williams et al.
Drug development and industrial pharmacy, 24(2), 157-162 (2004-12-21)
Freund's Incomplete Adjuvant (FIA), which is used in vaccine therapy, is a water-in-oil emulsion delivery system consisting of an aqueous internal phase containing an antigenic protein dispersed in an external phase containing a mixture of mannide monooleate and light mineral
Jerome Aucouturier et al.
Expert review of vaccines, 1(1), 111-118 (2003-08-12)
The development of adjuvants will represent a major challenge for this century. Indeed the need for safer vaccines leads to the development of a new generation of antigens like synthetic peptide, recombinant proteins or even vectored DNA. However, this is
Metabolic fate of mineral oil adjuvants using 14C-labeled tracers. II. Mannide monooleate.
J N Bollinger
Journal of pharmaceutical sciences, 59(8), 1088-1092 (1970-08-01)
Gaurav Batra et al.
Journal of virological methods, 167(1), 10-16 (2010-03-10)
A tetravalent dengue vaccine that can protect against all four serotypes of dengue viruses is a global priority. The host-receptor binding, multiple neutralizing epitope-containing carboxy-terminal region of the dengue envelope protein, known as domain III (EDIII), has emerged as a
James S McCarthy et al.
PloS one, 6(9), e24413-e24413 (2011-09-29)
In a previous Phase 1/2b malaria vaccine trial testing the 3D7 isoform of the malaria vaccine candidate Merozoite surface protein 2 (MSP2), parasite densities in children were reduced by 62%. However, breakthrough parasitemias were disproportionately of the alternate dimorphic form
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service